Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP288334.RAw6OZHhC6Hh4dcz_n-81zog7whKlzM6hGPwC-VRQoFhc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP288334.RAw6OZHhC6Hh4dcz_n-81zog7whKlzM6hGPwC-VRQoFhc130_assertion type Assertion NP288334.RAw6OZHhC6Hh4dcz_n-81zog7whKlzM6hGPwC-VRQoFhc130_head.
- NP288334.RAw6OZHhC6Hh4dcz_n-81zog7whKlzM6hGPwC-VRQoFhc130_assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP288334.RAw6OZHhC6Hh4dcz_n-81zog7whKlzM6hGPwC-VRQoFhc130_provenance.
- NP288334.RAw6OZHhC6Hh4dcz_n-81zog7whKlzM6hGPwC-VRQoFhc130_assertion evidence source_evidence_literature NP288334.RAw6OZHhC6Hh4dcz_n-81zog7whKlzM6hGPwC-VRQoFhc130_provenance.
- NP288334.RAw6OZHhC6Hh4dcz_n-81zog7whKlzM6hGPwC-VRQoFhc130_assertion SIO_000772 10883674 NP288334.RAw6OZHhC6Hh4dcz_n-81zog7whKlzM6hGPwC-VRQoFhc130_provenance.
- NP288334.RAw6OZHhC6Hh4dcz_n-81zog7whKlzM6hGPwC-VRQoFhc130_assertion wasDerivedFrom befree-2016 NP288334.RAw6OZHhC6Hh4dcz_n-81zog7whKlzM6hGPwC-VRQoFhc130_provenance.
- NP288334.RAw6OZHhC6Hh4dcz_n-81zog7whKlzM6hGPwC-VRQoFhc130_assertion wasGeneratedBy ECO_0000203 NP288334.RAw6OZHhC6Hh4dcz_n-81zog7whKlzM6hGPwC-VRQoFhc130_provenance.